HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Listerine Sensitivity Tops J&J Innovation Pipeline In '18

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

Johnson & Johnson will launch a Listerine mouthwash incorporating a class II device to address tooth sensitivity, Chief Technology Officer John Ghaim said during J&J’s Medical Devices & Consumer Analyst Day May 16. The company plans to launch 150 new products globally in 2018, which should help the company achieve sales ahead of the consumer health category.

You may also be interested in...

J&J Consumer Makes 'Aggressive' Shift In Digital Sales To Drive Growth

When J&J CEO Gorsky says, "We're not just sitting back, we're making aggressive moves in areas such as e-commerce, investments in that shift," his words are music to analysts' ears. J&J has OTC drug and other consumer health brands to drive growth, but it's missing the digital piece, they say.

J&J Consumer Health Brands Deliver Local Connections In Startup Style

J&J is growing Listerine mouthwash sales tapping into local tastes while continuing a global marketing push, says consumer business chief Jorge Mesquita. The firm also is developing strategy to make its brands “ambidextrous,” competing among small as well as large businesses.

International Headwinds Counter J&J's Consumer Growth Confidence

"Some much weaker markets and some macroeconomic conditions, particularly in China and India" prompt J&J to adjusts its overall and consumer business expectations, CFO Dominic Caruso says. Its consumer product revenues climbed 1.7% to $3.5bn in is latest quarter.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts